论文部分内容阅读
目的:观察拉米夫定联合肝泰乐治疗慢性乙型肝炎肝纤维化的疗效。方法:124例慢性乙肝患者随机分为实验组(A组,n=64)和对照组(B组,n=60),两组治疗前的基线资料无统计学差异(P>0.05)。对照组给予拉米夫定100mg,1次/d;实验组除按上述方法服用拉米夫定外,给予肝泰乐0.2g,3次/d,疗程1a。观察治疗前后乙肝病毒学标记物、肝功能、HBV-DNA、肝纤维化指标的改变。结果:治疗后A组和B组均有良好的病毒学应答,两组比较无统计学差异(P>0.05);实验组和对照组的肝功能指标均有明显改善,但实验组肝功能的指标的改善优于对照组,有统计学差异(P<0.05)。结论:拉米夫定联合肝泰乐对慢性乙型肝炎肝纤维化的改善具有优于单一用药的疗效,值得进一步推广。
Objective: To observe the curative effect of lamivudine combined with gantelle on chronic hepatitis B liver fibrosis. Methods: 124 patients with chronic hepatitis B were randomly divided into experimental group (n = 64 in group A) and control group (n = 60 in group B). There was no significant difference between the two groups before treatment (P> 0.05). The control group was given lamivudine 100mg once a day. In addition to the lamivudine treatment, the experimental group was given GTA 2.0g three times daily for 1 day. Observed before and after treatment of hepatitis B virus markers, liver function, HBV-DNA, liver fibrosis changes. Results: There was a good virological response in both groups A and B after treatment, with no significant difference between the two groups (P> 0.05). The liver function of the experimental group and the control group were significantly improved, but the liver function of the experimental group The improvement of the index was better than that of the control group (P <0.05). Conclusions: Lamivudine combined with Gantrez has better curative effect than single treatment on the improvement of liver fibrosis in chronic hepatitis B, which is worth further promotion.